Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Jun 26

2023

[News] Hua Medicine Announces the Potential of Dorzagliatin in Cognitive Dysfunction at ADA 2023

Hua Medicine (the "Company", HKEx stock code: 2552) today announces that multiple basic and clinical findings of HuaTangNing (華堂寧?, dorzagliatin), the Company’s global first-in-class glucokinase activator (GKA), were presented at the 83rd American Diabetes Association (ADA) Annual Scientific Sessions.

Jun 16

2023

[News] Hua Medicine will present multiple research results at the 2023 American Diabetes Association (ADA) Annual Scientific Sessions

Hua Medicine (the "Company", HKEx stock code: 2552) announced today that it will present multiple research results of HuaTangNing (華堂寧?, dorzagliatin), the Company’s first-in-class glucokinase activator (GKA), at the 83rd American Diabetes Association (ADA) Annual Scientific Sessions.

Mar 30

2023

[News] Hua Medicine Announces Multiple Personnel Appointments

Hua Medicine (the "Company", stock code: 2552.HK) today announces that Mr. George Chien Cheng Lin has been appointed Chief Strategy Officer of Hua Medicine. Mr. Lin will assume responsibility for corporate strategy for the Company, in addition to his current responsibilities for business development

Mar 30

2023

[News] Hua Medicine Announces 2022 Annual Results

Hua Medicine (the "Company", HKEx stock code: 2552), announced the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2022 (the "Reporting Period"). During the Reporting Period, the Company has achieved breakthrough development

Feb 16

2023

[News] Grand Opening Ceremony of Hua Medicine's First Online Flagship Store

Hua Medicine (the "Company", HKEx stock code: 2552.HK), today announces that the Company's first online flagship store is inaugurated on 111, Inc. (NASDAQ: YI), a leading tech-enabled healthcare platform company in China. On February 15th, Dr. Li Chen, the founder and CEO of Hua Medicine, and Dr. Gang Yu, the co-founder and executive chairman of 111, Inc. , jointly announce a grand opening of Hua Medicine’s first online flagship store at the Commercial Launch Event of HuaTangNing (華堂寧?).

Dec 20

2022

[News] WHO Lists Hua Medicine's Innovative First-in-Class Glucokinase Activator (GKA) HuaTangNing in its ATC Classification System

Hua Medicine (the "Company", HKEx stock code: 2552.HK), today announces that the ATC code of HuaTangNing, the Company's first-in-class glucokinase activator (Dorzagliatin tablets) has been formally published as final in WHO Collaborating Center (WHOCC) for Drug Statistics Methodology official website by the World Health Organization (WHO). The ATC code is A10BX18, which will be implemented in the WHO ATC Index in January 2023.

Nov 24

2022

[News] Hua Medicine Appoints Dr. Changhong LI as Chief Scientific Officer to Further Promote the Company's R&D Innovation

Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the appointment of Dr. Changhong LI, an experienced metabolic disease researcher, former member of the Institute of Diabetes, Obesity and Metabolism at the Perelman School of Medicine of the University of Pennsylvania and professional member of the American Diabetes Association

Oct 09

2022

[News] Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing(華堂寧?) Is Approved! New Type 2 Diabetes Treatment Paradigm to Begin in China

Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (華堂寧?) (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved

Aug 25

2022

Hua Medicine Announces 2022 Interim Results

Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2022 (the "Reporting Period"). The NDA for the company's core product dorzagliatin, a first-in-class innovative glucokinase activator (GKA) is under active review by the NMPA. The company is moving forward with preparations for the drug’s life cycle management for expansion of patient population and entering into new indications.

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(華堂寧?)

Focus Us

Copyright ? 2024 Hua Medicine (Shanghai) Co., Ltd. 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號: （滬）-非經(jīng)營-2022-0079
滬ICP備14036654號-1

滬公網(wǎng)安備 31011502013809號 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.